Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
Standard
Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. / Wölber, Linn; Müller, Volkmar; Zu Eulenburg, Christine Gräfin; Schwarz, Jörg; Carney, Walter; Jänicke, Fritz; Milde-Langosch, Karin; Mahner, Sven.
in: GYNECOL ONCOL, Jahrgang 117, Nr. 2, 2, 2010, S. 183-188.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
AU - Wölber, Linn
AU - Müller, Volkmar
AU - Zu Eulenburg, Christine Gräfin
AU - Schwarz, Jörg
AU - Carney, Walter
AU - Jänicke, Fritz
AU - Milde-Langosch, Karin
AU - Mahner, Sven
PY - 2010
Y1 - 2010
N2 - OBJECTIVE: Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples. METHODS: One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed. RESULTS: Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, p
AB - OBJECTIVE: Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples. METHODS: One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed. RESULTS: Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, p
M3 - SCORING: Zeitschriftenaufsatz
VL - 117
SP - 183
EP - 188
JO - GYNECOL ONCOL
JF - GYNECOL ONCOL
SN - 0090-8258
IS - 2
M1 - 2
ER -